How Has the Immunoglobulins Market Size Evolved in Recent Years?
The immunoglobulins market has seen considerable growth due to a variety of factors.
• Specifically, the size of the immunoglobulins market has seen rigorous growth in the past few years. Projections indicate an increase from $18.85 billion in 2024 to an estimated $20.53 billion in 2025, a compound annual growth rate (CAGR) of 8.9%.
The significant growth during the historic period is due to several factors - a higher incidence of immunodeficiency disorders, an increasing aging population, growing acceptance of immunoglobulins in hospitals, favourable government reimbursement policies, and a rise in chronic and autoimmune diseases.
What are the Market Size and Expected Growth Rates for the Immunoglobulins Market?
The immunoglobulins market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, rapid expansion is anticipated for the immunoglobulins market. It is projected to escalate to a worth of $31.59 billion by 2029, with a compound annual growth rate (CAGR) of 11.4%.
This significant rise during the forecast period can be ascribed to factors such as heightened investment in cutting-edge technology evolution, increased understanding of immunodeficiency therapies, a growing preference from physicians towards these therapies, the emergence of new markets, and broadening applications in sports and fitness. Some key trends expected to shape the forecast period include advancements in wearable and smart compression devices, the personalization of compression therapy solutions, the incorporation of compression therapies into wound care management, prioritization of patient comfort and compliance when it comes to compression therapies, and a trend towards cooperation between manufacturers and healthcare providers to deliver enhanced patient results.
Which Key Drivers Are Propelling The Immunoglobulins Market's Growth?
The rise in the elderly population is contributing to the growth of the immunoglobulins market. Older people are more vulnerable to infectious and auto-immune diseases. The immunoglobulin test measures the body's capacity to produce antibodies that defend against bacteria, viruses, and allergies. For example, a report released by the World Health Organization (WHO), a Switzerland-based organization in charge of global public health, indicated in October 2022 that one in six individuals globally is anticipated to be 60 or above by 2030. By 2050, the number of people aged 60 or over around the world will reach 2.1 billion. As a result of this growing elderly population, the demand for the immunoglobulins market is expected to rise during the projected timeframe.
What Are The Key Segments Within The Global Immunoglobulins Market?
The immunoglobulins market covered in this report is segmented –
1) By Product: IGG, IGA, IGM, IGE, IGD.
2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications
Subsegments:
1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)
2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA
3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM
4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE
5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD
Pre-Book The Immunoglobulins Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Immunoglobulins Market?
Top firms in the immunoglobulin market are focusing on product innovation, like intravenous immunoglobulins, to appeal to a wider consumer group, enhance sales, and boost income. For example, in September 2024, the South Korean biotech firm, GC Biopharma, introduced ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the American market. It is aimed at treating primary humoral immunodeficiency (PI) in individuals 17 years and older. The product is now accessible to patients via specialty pharmacies. Given the U.S.'s status as the world's biggest immunoglobulin market, valued roughly at $11.6 billion, this launch holds considerable significance. GC Biopharma aspires to reach $50 million in first-year sales for ALYGLO, with the goal of escalating it to $300 million by 2028. This aggressive growth blueprint includes collaborations with major pharmacy benefit managers and specialty pharmacies in the U.S., critical for the efficient distribution of immunoglobulin products.
Who Are the Key Players in the Immunoglobulins Market?
Major companies operating in the immunoglobulins market include:
• Baxter International Inc.
• CSL Behring LLC
• Grifols S. A.
• Octapharma AG
• China Biologic Products Holdings Inc.
• Kedrion SpA
• LFB SA
• Biotest AG
• Sanquin Blood Supply Foundation
• ADMA Biologics Inc.
• Option Care Health Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• Antibody Solutions
• Bio Products Laboratory Ltd.
• Immunovant Inc.
• Kamada Ltd.
• Emergent BioSolutions Inc.
• Fresenius Kabi AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Roche Holding AG
• Samsung Bioepis Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila Healthcare Limited
What are the Regional Insights into the Immunoglobulins Market?
North America was the largest region in the immunoglobulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
